Coronary artery bypass grafting in a patient with hemophilia B: continuous recombinant factor IX infusion as per the Japanese guidelines for replacement therapy

Tomoyuki Suzuki, Shunsuke Kawamoto, Kiichiro Kumagai, Osamu Adachi, Keisuke Kanda, Masaaki Ishikawa, Yoko Okitsu, Hideo Harigae, Shin Kurosawa, Yoshikatsu Saiki

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

We herein report our experience of successfully managing the hemostatic system by controlling serum factor IX levels throughout the perioperative period in a patient with hemophilia B. Coronary artery bypass grafting with cardiopulmonary bypass was planned for a 52-year-old man with moderate severity of hemophilia B. During surgery, recombinant factor IX (rFIX; BeneFIX® Pfizer Japan inc., Tokyo, Japan) was administered by bolus infusion followed by continuous infusion as per the guidelines of the Japanese Society on Thrombosis and Hemostasis. The operative course was uneventful without any considerable bleeding or complications.

Original languageEnglish
Pages (from-to)481-483
Number of pages3
JournalGeneral thoracic and cardiovascular surgery
Volume64
Issue number8
DOIs
Publication statusPublished - 2016 Aug 1

Keywords

  • Continuous infusion
  • Coronary artery bypass grafting
  • Hemophilia B
  • Recombinant factor IX

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Coronary artery bypass grafting in a patient with hemophilia B: continuous recombinant factor IX infusion as per the Japanese guidelines for replacement therapy'. Together they form a unique fingerprint.

Cite this